254 results match your criteria: "Milan (F.C.); and the Novartis Institutes for BioMedical Research[Affiliation]"

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.

View Article and Find Full Text PDF

: The treatment landscape for non-small cell lung cancer (NSCLC) has evolved significantly with the advent of immunotherapy. Nonetheless, uncertainty regarding optimal first-line treatments, special populations, and the feasibility of rechallenge remains. This study aims to investigate Italian oncologists' opinions on these aspects through a Delphi Survey.

View Article and Find Full Text PDF

Ovarian lesions are common and often incidentally detected. A critical shortage of expert ultrasound examiners has raised concerns of unnecessary interventions and delayed cancer diagnoses. Deep learning has shown promising results in the detection of ovarian cancer in ultrasound images; however, external validation is lacking.

View Article and Find Full Text PDF

Background: Activated Phosphoinositide 3-Kinase (PI3K) δ Syndrome (APDS), an inborn error of immunity due to upregulation of the PI3K pathway, leads to recurrent infections and immune dysregulation (lymphoproliferation and autoimmunity).

Methods: Clinical and genetic data of 28 APDS patients from 25 unrelated families were collected from fifteen Italian centers.

Results: Patients were genetically confirmed with APDS-1 (n = 20) or APDS-2 (n = 8), with pathogenic mutations in the PIK3CD or PIK3R1 genes.

View Article and Find Full Text PDF

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

N Engl J Med

December 2024

From Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (K.L.J.); University Hospitals Leuven, Leuven, Belgium (P.N.); Hospital María Curie, Buenos Aires (M.L.C.); Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (S.-B.K.); National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan (E.T.); Institut Jules Bordet, Hôpital Universitaire de Bruxelles, Brussels (P.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (C.S.); Baylor University Medical Center, Texas Oncology, U.S. Oncology, Dallas (J.O.); the Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, Ludwig Maximilians University Munich University Hospital, Munich, Germany (N.H.); the University of North Carolina at Chapel Hill, Chapel Hill (L.A.C.); the University of Milan, Milan (G.C.); the European Institute of Oncology, IRCCS, Milan (G.C.); Hospital Arnau de Vilanova, Valencia, Spain (A.L.-C.); Garvan Institute of Medical Research and University of New South Wales, Sydney (E.L.); Hospital de Oncología, Centro Médico Nacional Siglo XXI, Mexico City (M.L.G.T.); Yonsei University College of Medicine, Seoul, South Korea (J.S.); the Mastology Department, Women's Health Hospital, São Paulo (A.M.); Harbin Medical University Cancer Hospital, Harbin, China (Q.Z.); National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei (C.-S.H.); the Division of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan (C.-C.H.); Filios Alta Medicina, Monterrey, Mexico (J.L.M.R.); the Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain (M.R.B.); the Department of Breast Surgery, Chiba Cancer Center Hospital, Chiba, Japan (R.N.); Eli Lilly, Indianapolis (K.R.P., C.C.L., E.B., S.C., X.A.W., L.M.S.); and Institut Curie and University of Versailles Saint-Quentin-en-Yvelines-Paris-Saclay University, Paris (F.-C.B.).

Background: Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα ().

Methods: In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer that recurred or progressed during or after aromatase inhibitor therapy, administered alone or with a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Patients were assigned in a 1:1:1 ratio to receive imlunestrant, standard endocrine monotherapy, or imlunestrant-abemaciclib.

View Article and Find Full Text PDF

Background: To combat the high prevalence of physical inactivity among children, there is an urgent need to develop and implement real-world interventions and policies that promote physical activity (PA) and reduce sedentary behaviour (SB). To inform policy makers, the current body of evidence for children's PA/SB interventions needs to be translated.

Objectives: The current systematic review and meta-analysis aimed to identify modifiable determinants of device-measured PA and SB targeted in available intervention studies with randomized controlled trial (RCT) and controlled trial (CT) designs in children and early adolescents (5-12 years) and to quantify the effects of the interventions within their respective settings on the determinants of PA/SB and the outcomes PA and SB.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to confirm the reliability of measuring choriocapillaris flow deficit (CCFD) within a specific macular grid and to track these measurements over time.
  • Researchers utilized advanced imaging technology to gather data, excluding certain areas in the scans to accurately calculate CCFD percentages in both normal eyes and those with eye conditions.
  • The findings showed that the methodology is effective for monitoring changes in CCFD, particularly in cases where drusen (eye abnormalities) resolved, demonstrating the practicality of the grid strategy for longitudinal studies.
View Article and Find Full Text PDF
Article Synopsis
  • Opioids are commonly used to manage cancer pain, but 10%-20% of patients either do not respond well or suffer from negative side effects, potentially due to genetic differences.
  • A genome-wide association study (GWAS) was conducted on cancer patients across Europe to find genetic markers related to opioid-induced nausea and vomiting.
  • The study identified 65 genetic variants linked to nausea-vomiting scores, including variants in the NPAS2 gene, paving the way for more personalized cancer pain management strategies through further research.
View Article and Find Full Text PDF

Background: Managing metabolism for optimal training, performance, and recovery in medium-to-high-level endurance runners involves enhancing energy systems through strategic nutrient intake. Optimal carbohydrate intake before, during, and after endurance running can enhance glycogen stores and maintain optimal blood glucose levels, influencing various physiological responses and adaptations, including transitory post-endurance inflammation. This randomized trial investigates the impact of a high-dose 2:1 maltodextrin-fructose supplementation to medium-to-high-level endurance runners immediately before, during, and after a 15 km run at 90% VO intensity on post-exercise inflammatory stress.

View Article and Find Full Text PDF

Tumor-associated macrophages (TAMs), often adopting an immunosuppressive M2-like phenotype, correlate with unfavorable cancer outcomes. Our investigation unveiled elevated expression of the butyrophilin (BTN)2A1 in M2-like TAMs across diverse cancer types. We developed anti-BTN2A1 monoclonal antibodies (mAbs), and notably, one clone demonstrated a robust inhibitory effect on M2-like macrophage differentiation, inducing a shift toward an M1-like phenotype both in vitro and ex vivo in TAMs from patients with cancer.

View Article and Find Full Text PDF
Article Synopsis
  • Cervical cancer still has a poor prognosis despite treatment advances, especially for patients progressing after chemotherapy and immunotherapy, where traditional options are limited.
  • Antibody-drug conjugates (ADCs), like tisotumab vedotin, show promise for recurrent/metastatic cervical cancer, demonstrating improved response rates and progression-free survival in trials.
  • Key unresolved issues include the optimal timing for ADC use, combination therapy strategies to combat resistance, and managing specific toxicities, with a future focus on biomarker-driven patient selection to enhance treatment effectiveness and safety.
View Article and Find Full Text PDF

Gold nanorod-assisted theranostic solution for nonvisible residual disease in bladder cancer.

Proc Natl Acad Sci U S A

September 2024

Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy.

Residual nonvisible bladder cancer after proper treatment caused by technological and therapeutic limitations is responsible for tumor relapse and progression. This study aimed to demonstrate the feasibility of a solution for simultaneous detection and treatment of bladder cancer lesions smaller than one millimeter. The α5β1 integrin was identified as a specific marker in 81% of human high-grade nonmuscle invasive bladder cancers and used as a target for the delivery of targeted gold nanorods (GNRs).

View Article and Find Full Text PDF

Topographical Quantification of Retinal Fluid in Type 3 MNV and Associations With Short-Term Visual Outcomes.

Am J Ophthalmol

January 2025

Department of Surgical Sciences, University of Turin (F.C., A.G., M.R., E.B.), Turin, Italy; Department of Ophthalmology, City of Health and Science Hospital (F.C., A.G., M.R., E.B.), Turin, Italy. Electronic address:

Purpose: This study aims to quantify the volume of intraretinal fluid (IRF), subretinal fluid (SRF), and subretinal pigment epithelium (sub-RPE) fluid in treatment-naïve Type 3 macular neovascularization (MNV) eyes with age-related macular degeneration (AMD) and to investigate the correlation of these fluid volumes with visual acuity (VA) outcomes at baseline and following antivascular endothelial growth factor (VEGF) treatment.

Design: Retrospective, clinical cohort study.

Methods: In this study, we analyzed patients diagnosed with exudative AMD and treatment-naïve Type 3 MNV undergoing a loading dose of anti-VEGF therapy.

View Article and Find Full Text PDF

Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation.

N Engl J Med

November 2024

From the Department of Cardiology of German Heart Center Charité and the Institute of Health Center for Regenerative Therapies, German Center for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin (S.D.A., M.D., W.H.), the Department of Cardiology, Angiology, and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, the Berlin Institute of Health, and DZHK Partner Site Berlin (U.L.), Deutsches Herzzentrum der Charité, the Department of Cardiology, Angiology, and Intensive Care Medicine, Campus Charité Mitte, the Center for Cardiovascular Telemedicine, and DZHK Partner Site Berlin, Charité Universitätsmedizin (F.K.), Berlin, the Departments of Cardiology and Pneumology (S.D.A., M.D., G.H., W.S.) and Medical Statistics (T.F., M.P.) and the Clinical Trial Unit (J.H.), University Medical Center Göttingen, and the Heart Center, Department of Cardiology (W.S.), Georg August University of Göttingen, DZHK Partner Site Göttingen, Göttingen, the Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz (R.S.B., M. Geyer, T.F.R.), Mainz, the Department of Cardiology, Pulmonology, and Vascular Medicine, University Hospital Düsseldorf, Medical Faculty of the Heinrich Heine University Düsseldorf, and Cardiovascular Research Institute Düsseldorf, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf (M. Kelm), the Department of Rhythmology, University Heart Center Lübeck, University Hospital Schleswig-Holstein, Lübeck (K.-H.K.), the West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, University Hospital Essen, University Duisburg-Essen, Essen (T.R.), the Heart and Vascular Center, Bad Bevensen (U.S.), the Department of Internal Medicine I, Cardiology, University Hospital Jena, Jena (P.C.S.), the Institute for Cardiovascular Regeneration, Goethe University Frankfurt, and DZHK Partner Site Rhein-Main, Frankfurt am Main (A.Z.), the Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, and DZHK Partner Site Hamburg-Kiel-Lübeck, Hamburg (M. Karakas), the Department of Cardiology, Rostock University Medical Center, Rostock (A.Ö.), the Department of Medicine, Heart and Vascular Center, Division of Cardiology and Vascular Medicine, Johanniter Hospital Stendal, Stendal (M. Gross), the Mid-German Heart Center, Department of Cardiology, Angiology, and Intensive Care Medicine, University Hospital Halle, Halle (J.T.) - all in Germany; the Department of Medicine, University of Mississippi Medical Center, Jackson (J.B.); Baylor Scott and White Research Institute, Dallas (J.B., M.S.K.), Baylor Scott and White the Heart Hospital Plano, Plano (M.S.K.), and the Department of Medicine, Baylor College of Medicine, Temple (M.S.K.) - all in Texas; the Department of Translational Medicine, University of Ferrara, Ferrara (R.F.), the Cardiac Surgery Unit, IRCCS San Raffaele Scientific Institute, Milan (O.A.), ANMCO Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Heart Care Foundation, Florence (A.P.M.), and the Institute of Cardiology, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, and the Department of Medical and Surgical Specialties, Radiologic Sciences and Public Health, University of Brescia, Brescia (M.M., M.A.) - all in Italy; the Division of Cardiovascular Medicine, Ohio State University, Columbus (W.T.A.); the Department of Cardiology, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano (A.A.), and the Center for Translational and Experimental Cardiology, Department of Cardiology, University Hospital Zurich, University of Zurich, Zurich (F.R.) - both in Switzerland; the Heart Institute, Hospital Universitari Germans Trias i Pujol, Barcelona (A.B.-G., E.S.-V.), and the Department of Cardiology, Hospital Universitario Ramón y Cajal, and Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid (J.L.Z.) - all in Spain; the School of Cardiovascular and Metabolic Health, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (J.G.F.C., M.C.P.); the Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens (G.F.), and the Department of Transcatheter Heart Valves, Hygeia Hospital (K.S., M.C., P.K., K.P.), Athens, and the Department of Cardiology, St. Luke's Hospital (N.M., E.K.T.), and the European Interbalkan Medical Center (V.N., I.N., K.P.), Thessaloniki - all in Greece; the Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen (F.G.); Unité Formation et Recherche Médecine, Université de Paris-Cité, site Bichat, Laboratoire de Recherche Vasculaire Translationnelle, INSERM, Groupe Hospitalier Bichat, Paris (A.V.); the Division of Cardiology, General Hospital Murska Sobota, Murska Sobota, and the Faculty of Medicine, University of Ljubljana, Ljubljana - both in Slovenia (M.L.); the Division of Cardiology and Structural Heart Diseases (G.S., W.W.) and the Department of Cardiology, Congenital Heart Diseases, and Electrotherapy (Z.K.), Medical University of Silesia, Katowice, the Institute of Heart Diseases, Medical University and University Hospital, Wrocław (K.R., P.P.), and the Department of Interventional Cardiology, Department of Radiology and Diagnostic Imaging, John Paul II Hospital, Krakow (Ł.W.) - all in Poland; and Centro Academico de Medicina de Lisboa, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal (F.J.P.).

Article Synopsis
  • The study examined the effectiveness of transcatheter mitral-valve repair in patients suffering from heart failure and functional mitral regurgitation, comparing it to standard medical therapy.
  • In a trial with 505 patients, results showed that those who received the device had significantly lower rates of hospitalizations for heart failure and cardiovascular death compared to those who only received medical therapy.
  • Additionally, patients in the device group experienced a greater improvement in health status, as measured by the Kansas City Cardiomyopathy Questionnaire, indicating better outcomes with the transcatheter procedure.
View Article and Find Full Text PDF

Since the 1960s, cardiologists have adopted several binary classification systems for acute myocardial infarction (MI) that facilitated improved patient management. Conversely, for chronic stable manifestations of myocardial ischemia, various classifications have emerged over time, often with conflicting terminology-eg, "stable coronary artery disease" (CAD), "stable ischemic heart disease," and "chronic coronary syndromes" (CCS). While the 2019 European guidelines introduced CCS to impart symmetry with "acute coronary syndromes" (ACS), the 2023 American guidelines endorsed the alternative term "chronic coronary disease.

View Article and Find Full Text PDF

Cemiplimab has demonstrated relevant clinical activity in cutaneous squamous cell carcinoma (cSCC) but mechanisms of primary and acquired resistance to immunotherapy are still unknown. We collected clinical data from locally advanced and/or metastatic cSSC patients treated with cemiplimab in two Italian University centers. In addition, gene expression analysis by using Nanostring Technologies platform to evaluate 770 cancer- and immune-related genes on 20 tumor tissue samples (9 responders and 11 non-responders to cemiplimab) was performed.

View Article and Find Full Text PDF

(1) Background: Functional abdominal bloating and distension (FAB/FAD) are common disorders of the gut-brain interaction. Their physiopathology is complex and not completely clarified, although gut microbiota imbalances play a central role. The treatment of FAB/FAD still represents a clinical challenge for both patients and healthcare providers.

View Article and Find Full Text PDF

What Not to Overlook in the Management of Patients with Type 2 Diabetes Mellitus: The Nephrological and Hepatological Perspectives.

Int J Mol Sci

July 2024

SC Medicina Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, 20122 Milan, Italy.

Article Synopsis
  • Diabetes mellitus (DM) has significant impacts on kidney and liver functions, leading to conditions like diabetic kidney disease (DKD) and metabolic dysfunction-associated steatotic liver disease (MASLD).
  • Management strategies for DKD include lifestyle changes and medications focusing on blood pressure and blood sugar control, while lifestyle modifications like weight loss and a Mediterranean diet are essential for MASLD.
  • There's a critical need for screening and tailored care for patients with DM and liver issues, especially in unique populations such as those on hemodialysis or kidney transplant recipients, highlighting the importance of a multidisciplinary approach.
View Article and Find Full Text PDF

Background And Purpose: Mechanical thrombectomy (MT) along with emergent carotid stent placement (eCAS) has been suggested to have a greater benefit in patients with tandem lesions (TL), compared with other strategies of treatment. Nonetheless, there is no agreement on whether the intracranial occlusion should be treated before the cervical ICA lesion, or vice versa. In this retrospective multicenter study, we sought to compare clinical and procedural outcomes of the 2 different treatment approaches in patients with TL.

View Article and Find Full Text PDF

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.

N Engl J Med

July 2024

From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France (L.P.-B.); the Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal (L.P.-B.), and the Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB (R.P.) - both in Canada; the Crohn's and Colitis Center at the Baton Rouge General and the GI Alliance, Baton Rouge, LA (J.C.C.); the Henry D. Janowitz Division of Gastroenterology, Department of Medicine (J.-F.C.), and the Susan and Leonard Feinstein IBD Center (M.D.), Icahn School of Medicine at Mount Sinai, New York; the Department of Pathophysiology and Transplantation, Università degli Studi di Milano and the Unit of Gastroenterology and Endoscopy, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico di Milano (F.C.), and Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele (S.D.) - both in Milan; the Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam (G.D.); the Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven (M.F.), and the Imelda GI Clinical Research Center, Department of Gastroenterology, Imelda General Hospital, Bonheiden (P.B.) - both in Belgium; the Department of Medicine I, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel (S.S.), the Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen (R.A.), and the Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin (B.S.) - all in Germany; the Centre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (J.O.L.), the Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust (P.M.I.), and the School of Immunology and Microbial Sciences, King's College London (P.M.I.) - all in London; the Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China (Q.C.); and AbbVie, North Chicago, IL (E.N., K.W., T.A., K.K., W.R.D., V.P., X.H., S.B., L.S.).

Article Synopsis
  • A phase 3b clinical trial was conducted to compare the effectiveness and safety of risankizumab and ustekinumab in patients with moderate-to-severe Crohn's disease who didn't respond to anti-TNF therapy.
  • The study evaluated two primary outcomes: clinical remission at week 24 and endoscopic remission at week 48, with risankizumab being tested for noninferiority and superiority, respectively.
  • Results showed that risankizumab was not only noninferior to ustekinumab for clinical remission but also superior for endoscopic remission, with significant improvements reported in patients receiving risankizumab.
View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated how various cardiometabolic risk factors, such as metabolic syndrome and individual factors like high fasting glucose and low HDL cholesterol, impact the progression of coronary plaque and the likelihood of major cardiovascular events in patients with stable coronary artery disease.
  • - In a cohort of 1,200 patients followed over several years, 28% experienced rapid coronary plaque progression, identified primarily through increased atheroma volume, which indicates worsening arterial health.
  • - The findings suggest that a combination of risk factors, particularly high blood sugar and blood pressure, significantly forecast both plaque progression and serious cardiovascular incidents, highlighting the importance of monitoring these factors in at-risk patients.
View Article and Find Full Text PDF

Mixed Shock Complicating Cardiogenic Shock: Frequency, Predictors, and Clinical Outcomes.

Circ Heart Fail

July 2024

Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy (L.B., G.F., A.C., V.R., B.P., L.C., M.G., V.P., S.S., F.C., S.A., A.M.S.).

Article Synopsis
  • * In a study of 200 patients with pure CS, 24.5% developed MS, with lower blood pressure, liver damage, and suspected infection identified as independent predictors of its occurrence.
  • * MS is associated with higher in-hospital mortality (53.1% vs. 27.8%) and longer hospital stays, while using temporary mechanical support can reduce the chances of death for affected patients.
View Article and Find Full Text PDF

Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders.

Neurol Neuroimmunol Neuroinflamm

September 2024

From the Experimental and Clinical Research Center (F.C.O., H.G.Z., S.M., C.B., L.M.M., A.U.B., F.P.), Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin; Neuroscience Clinical Research Center (F.C.O., H.G.Z., S.M., C.B., L.M.M., A.U.B., F.P.); Department of Neurology (F.C.O., F.P.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Einstein Center Digital Future (H.G.Z.), Berlin, Germany; Kashani MS Center (F.A.), Isfahan University of Medical Sciences; School of Advanced Technologies in Medicine and Medical Image and Signal Processing Research Center (R.K.); Department of Ophthalmology (A.D., M. Pourazizi), Isfahan Eye Research Center, Isfahan University of Medical Sciences, Iran; Department of Neurology (L.P., A.D.C.), KS Hegde Medical Academy, Nitte University, Mangalore, India; Department of Neurology (O.A., P.A., M. Ringelstein), Medical Faculty, Heinrich Heine University Düsseldorf; Department of Neurlogy (P.A.), Kliniken Maria Hilf Mönchengladbach; Centre for Neurology and Neuropsychiatry (M. Ringelstein), Landschaftsverband Rheinland-Klinikum Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Germany; Hospital Clinic of Barcelona-Institut d'Investigacions (E.H.M.-L., B.F.S.D., P.V.), Biomèdiques August Pi Sunyer, (IDIBAPS), Barcelona, Spain; Departments of Neurology (N.A.), Slagelse Hospitals, Denmark, Institute of Regional Health Research; Institute of Molecular Medicine (N.A.), University of Southern Denmark, Odense, Denmark; Service de Neurologie (R.M., A.C.-C.), Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, France; Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (A.C.-C.), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, Spain; Experimental Neurophysiology Unit (L.L., M. Pisa, M. Radaelli), Institute of Experimental Neurology (INSPE) Scientific Institute San Raffaele and University Vita-Salute San Raffaele, Milan, Italy; Department of Neurology (J.P., A.R.-F., M.I.S.L.); Department of Ophthalmology (S.S.), Oxford University Hospitals, National Health Service Trust, United Kingdom; Neurology Service (J.D.S., T.S.), University Hospital of Strasbourg, France; Department of Medicine (M.R.Y.), Divisions of Molecular Medicine and Infectious Diseases, Harbor-University of California at Los Angeles (UCLA) Medical Center, and Lundquist Institute for Biomedical Innovation, Torrance; Department of Medicine (M.R.Y.), David Geffen School of Medicine at UCLA, Los Angeles; Departments of Ophthalmology and Visual Sciences (T.J.S.), Kellogg Eye Center; Division of Metabolism (T.J.S.), Endocrine and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor; and Department of Pediatrics (L.J.C.), University of Utah.

Article Synopsis
  • The study aimed to describe the clinical features of double-antibody seronegative neuromyelitis optica spectrum disorders (DN-NMOSD), focusing on how these disorders affect the retina.
  • Researchers analyzed data from 25 individuals with DN-NMOSD and compared it to those with aquaporin-4 antibody positive neuromyelitis optica (AQP4-NMOSD) and healthy controls, using optical coherence tomography (OCT) to assess retinal damage.
  • The findings revealed significant thinning of the retinal nerve fiber layer and ganglion cell layers in DN-NMOSD patients, even after just one optic neuritis episode, indicating severe retinal damage and neurodegeneration regardless of an ON history.
View Article and Find Full Text PDF

Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness Scores.

Neurol Neuroimmunol Neuroinflamm

September 2024

From the Charité - Universitätsmedizin Berlin (T.-Y.L., S.M., S.A., C.C., S. Samadzadeh, J.B.-S., T.S.-H., A.U.B., H.G.Z., F.P.); Experimental and Clinical Research Center (T.-Y.L., S.M., S.A., C.C., S. Samadzadeh, J.B.-S., T.S.-H., A.U.B., H.G.Z., F.P.), a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin; Max-Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) (T.-Y.L., S.M., S.A., C.C., S. Samadzadeh, J.B.-S., T.S.-H., A.U.B., H.G.Z., F.P.); Neuroscience Clinical Research Center (S.M., S.A., C.C., J.B.-S., T.S.-H., H.G.Z., F.P.); Department of Psychiatry and Psychotherapy (C.C.), Charité - Universitätsmedizin Berlin, Germany; Department of Neurology (S. Saidha, P.A.C., K.C.F.); Department of Epidemiology (K.C.F.), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Department of Regional Health Research and Molecular Medicine (S. Samadzadeh), University of Southern Denmark, Odense; Department of Neurology (S. Samadzadeh), Slagelse Hospital, Denmark; Department of Neurology (P. Villoslada), Hospital Del Mar - Pompeu Fabra University; Neuroimmunology and Multiple Sclerosis Unit (S.L.), Hospital Clinic Barcelona and IDIBAPS, Barcelona, Spain; Department of Neurology (A.J.G.), University of California San Francisco; Department of Neurology (J.L.P.), Charles University in Prague, Czech Republic; Moorfield's Eye Hospital (A.P.), The National Hospital for Neurology and Neurosurgery, Queen Square Institute of Neurology, University College London, United Kingdom; Neuro-ophthalmology Expert Center (A.P.), Amsterdam UMC, Netherlands; Experimental Neurophysiology Unit (L.L.), Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute; Vita-Salute San Raffaele University (L.L.), Milan, Italy; Miguel Servet University Hospital (E.G.-M.), Zaragoza; Department of Neurology (C.O.-G.), Hospital Clínico Universitario San Carlos, Madrid, Spain; Department of Neurology (O.O., P. Vermersch); Department of Neuroradiology (O.O., P. Vermersch), Centre Hospitalier Universitaire de Lille, France; Departments of Neurology (L.J.B., R.K.), Population Health and Ophthalmology, NYU Grossman School of Medicine, NY; Department of Neurology (P.A., O.A.), Heinrich-Heine-University, Düsseldorf, Germany; Departments of Clinical Neurosciences and Surgery Cumming School of Medicine (F.C.), University of Calgary, Alberta, Canada; Clinic of Optic Neuritis and Clinic of Multiple Sclerosis (J.F.), Department of Neurology, Rigshospitalet - Glostrup, Denmark; Department of Neurosciences (A.U., M.C.), Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Italy; Laboratory of Neuroimmunology (E.M.F., T.C.F.), Professor Lawrence Steinman, Stanford University School of Medicine, Palo Alto, CA; Department of Neurology (K.R., F.P.), Charité - Universitätsmedizin Berlin; and Einstein Center Digital Future (H.G.Z.), Berlin, Germany.

Article Synopsis
  • The study aims to evaluate how age-adjusted scores from retinal optical coherence tomography (OCT) can predict future disease activity and disability worsening in people with multiple sclerosis (PwMS).
  • Researchers created age-adjusted reference values for specific retinal measurements using data from healthy eyes and transformed existing data from PwMS into these scores for comparison.
  • Results showed that lower scores (pRNFL-z) were linked to a greater risk of disability worsening, with significant findings from two different cohorts highlighting the importance of retinal imaging in assessing MS progression.
View Article and Find Full Text PDF